Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: We used next-generation sequencing (NGS) to analyze resistance-associated substitutions (RASs) and retreatment outcomes in patients with chronic hepatitis C virus (HCV) infection who failed direct-acting antiviral agent (DAA) treatment in South Korea. Methods: Using prospectively collected data from the Korean HCV cohort study, we recruited 36 patients who failed DAA treatment in 10 centers between 2007 and 2020; 29 blood samples were available from 24 patients. RASs were analyzed using NGS. Results: RASs were analyzed for 13 patients with genotype 1b, 10 with genotype 2, and one with genotype 3a. The unsuccessful DAA regimens were daclatasvir+asunaprevir (n=11), sofosbuvir+ribavirin (n=9), ledipasvir/sofosbuvir (n=3), and glecaprevir/pibrentasvir (n=1). In the patients with genotype 1b, NS3, NS5A, and NS5B RASs were detected in eight, seven, and seven of 10 patients at baseline and in four, six, and two of six patients after DAA failure, respectively. Among the 10 patients with genotype 2, the only baseline RAS was NS3 Y56F, which was detected in one patient. NS5A F28C was detected after DAA failure in a patient with genotype 2 infection who was erroneously treated with daclatasvir+asunaprevir. After retreatment, 16 patients had a 100% sustained virological response rate. Conclusions: NS3 and NS5A RASs were commonly present at baseline, and there was an increasing trend of NS5A RASs after failed DAA treatment in genotype 1b. However, RASs were rarely present in patients with genotype 2 who were treated with sofosbuvir+ribavirin. Despite baseline or treatment-emergent RASs, retreatment with pan-genotypic DAA was highly successful in Korea, so we encourage active retreatment after unsuccessful DAA treatment.
Abstract
Background/Aims: We used next-generation sequencing (NGS) to analyze resistance-associated substitutions (RASs) and retreatment outcomes in patients with chronic hepatitis C virus (HCV) infection who failed direct-acting antiviral agent (DAA) treatment in South Korea. Methods: Using prospectively collected data from the Korean HCV cohort study, we recruited 36 patients who failed DAA treatment in 10 centers between 2007 and 2020; 29 blood samples were available from 24 patients. RASs were analyzed using NGS. Results: RASs were analyzed for 13 patients with genotype 1b, 10 with genotype 2, and one with genotype 3a. The unsuccessful DAA regimens were daclatasvir+asunaprevir (n=11), sofosbuvir+ribavirin (n=9), ledipasvir/sofosbuvir (n=3), and glecaprevir/pibrentasvir (n=1). In the patients with genotype 1b, NS3, NS5A, and NS5B RASs were detected in eight, seven, and seven of 10 patients at baseline and in four, six, and two of six patients after DAA failure, respectively. Among the 10 patients with genotype 2, the only baseline RAS was NS3 Y56F, which was detected in one patient. NS5A F28C was detected after DAA failure in a patient with genotype 2 infection who was erroneously treated with daclatasvir+asunaprevir. After retreatment, 16 patients had a 100% sustained virological response rate. Conclusions: NS3 and NS5A RASs were commonly present at baseline, and there was an increasing trend of NS5A RASs after failed DAA treatment in genotype 1b. However, RASs were rarely present in patients with genotype 2 who were treated with sofosbuvir+ribavirin. Despite baseline or treatment-emergent RASs, retreatment with pan-genotypic DAA was highly successful in Korea, so we encourage active retreatment after unsuccessful DAA treatment.
참고문헌 (40)
- Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sectorstrategies 2016–2021: actions for impact, "World Health Organization", World Health Organization, ~ (2021)
- Omar Alshuwaykh, "Current and future strategies for the treatment of chronic hepatitis C", Clinical and Molecular Hepatology, 27(2), pp.246~256 (2021), 대한간학회[DOI]
- Perelson AS, "New kinetic modelsfor the hepatitis C virus", Hepatology, 42, pp.749~754 (2005)
- Nguyen LT, "Naturally occurring HCV NS5A", B inhibitor resistance-associated mutations to directacting antivirals, 2016, pp.21, 447~453
- Prabdial-Sing N, "Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa", Antiviral Res, 127, pp.90~98 (2016)
- Dietz J, "Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals", Gastroenterology, 154, pp.976~988 (2018)
- Jang ES, "The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015", Hepatol Int, 13, pp.599~608 (2019)
- Kyung-Ah Kim, "Prevalence, Awareness, and Treatment of Hepatitis C Virus Infection in South Korea: Evidence from the Korea National Health and Nutrition Examination Survey", Gut and Liver, 14(5), pp.644~651 (2020), 거트앤리버 소화기연관학회협의회[DOI]
- 정숙향, "Current status of hepatitis C virus infection and countermeasures in South Korea", Epidemiology and Health, 39, pp.1~7 (2017), 한국역학회[DOI]
- Kwon JH, "Clinical outcomes after the introduction of direct antiviral agentsfor patients infected with genotype 1b hepatitis C virus depending on the regimens : A multicenter study in Korea", J Med Virol, 91, pp.1104~1111 (2019)
- Jang ES, "Real-life effectiveness and safety of the daclatasvir", asunaprevir combination therapy for genotype 1b chronic hepatitis C patients : An emphasis on the pretreatment NS5A resistance-associated substitution test, 2019, pp.91, 2158~2165
- Jang Eun Sun, "Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose", Gut and Liver, 14(6), pp.775~782 (2020), 거트앤리버 소화기연관학회협의회[DOI]
- Baumert TF, "Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges", Gastroenterology, 156, pp.431~445 (2019)
- Prenner SB, "Hepatocellular carcinoma decreases the chance of successful hepatitis C virustherapy with direct-acting antivirals", J Hepatol, 66, pp.1173~1181 (2017)
- Li H, "Fast and accurate short read alignment with Burrows-Wheeler transform", Bioinformatics, 25, pp.1754~1760 (2009)
- Li H, "1000 Genome Project Data Processing Subgroup. The Sequence Alignment", Map format and SAMtools, 2009, pp.25, 2078~2079
- Tarasov A, "Sambamba : fast processing of NGS alignment formats", Bioinformatics, 31, pp.2032~2034 (2015)
- Cingolani P, "A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogasterstrainw1118; iso-2; iso-3", Fly(Austin), 6, pp.80~92 (2012)
- Yang X, "De novo assembly of highly diverse viral populations", BMC Genomics, 13, pp.475~ (2012)
- Ji F, "Systematic review with meta-analysis : effectiveness and tolerability of interferon-free direct-acting antiviral regimensfor chronic hepatitis C genotype 1 in routine clinical practice in Asia", Aliment Pharmacol Ther, 47, pp.550~562 (2018)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
- Sorbo MC, "Hepatitis C virus drug resistance associated substitutions and their clinical relevance : Update 2018", Drug Resist Updat, 37, pp.17~39 (2018)
- Yu JH, "Real-life prevalence of resistanceassociated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C", Virol J, 14, pp.164~ (2017)
- Howe AYM, "Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals", JHEP Rep, 4, pp.100462~ (2022)
- Sarrazin C, "Treatment failure with DAA therapy : Importance of resistance", J Hepatol, 74, pp.1472~1482 (2021)
- Wu R, "Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide", Infect Drug Resist, 12, pp.2987~3015 (2019)
- Mawatari S, "The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir", PLoS One, 13, pp.e0198642~ (2018)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C : Final update of the series", J Hepatol, 73, pp.1170~1218 (2020)
- Mawatari S, "Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy", Hepatol Res, 50, pp.453~465 (2020)
- Xu S, "In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to-6", Antivir Ther, 22, pp.587~597 (2017)
- Gane EJ, "Nucleotide polymerase inhibitor sofosbuvir plusribavirin for hepatitis C", N Engl J Med, 368, pp.34~44 (2013)
- Keating GM, "Sofosbuvir : a review of its use in patients with chronic hepatitis C", Drugs, 74, pp.1127~1146 (2014)
- Svarovskaia ES, "Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials", Clin Infect Dis, 59, pp.1666~1674 (2014)
- Chen CY, "Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C : A real-world nationwide hepatitis C virusregistry programme in Taiwan", Liver Int, 41, pp.1265~1277 (2021)
- Shen C, "Efficacy and safety of glecaprevir", pibrentasvir in HCV patients with previous direct-acting antiviral therapy failures: A meta-analysis, 2020, pp.7, 592472~
- Seong MH, "Clinical and epidemiological features of hepatitis C virus infection in South Korea : a prospective, multicenter cohort study", J Med Virol, 85, pp.1724~1733 (2013)
- Ghany MG, "Hepatitis C Guidance 2019 Update : American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C VirusInfection", Hepatology, 71, pp.686~721 (2020)
- Krishnan P, "Pooled resistance analysis in patients with hepatitis C virus genotype 1 to 6 infection treated with glecaprevir-pibrentasvir in phase 2 and 3 clinical trials", Antimicrob Agents Chemother, 62, pp.e01249-18~ (2018)
- Manso CF, "Technical validation of a hepatitis C virus whole genome sequencing assay for detection of genotype and antiviral resistance in the clinical pathway", Front Microbiol, 11, pp.576572~ (2020)
- Caputo V, "Detection of low-level HCV variants in DAA treated patients : comparison amongst three different NGS data analysis protocols", Virol J, 17, pp.103~ (2020)